Amgen (AMGN)

67.36 +0.52  +0.78%  Feb 10, 11:00PM Go Pro
Watch
View Full Chart AMGN Price Chart

Key Stats

Market Cap 59.04B
Revenue Growth 3.44%
Profit Margin 23.51%
Earnings Yield 5.98%
Dividend Yield 2.20%
Earnings Per Share TTM 4.03
PE Ratio 16.71
Price / Sales Ratio 3.79
52 Week High 70.00
52 Week Low 47.66
Beta 0.45
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

Feb 10 Final Glance: Biotechnology companies
Feb 10 TEXT-Fitch:FDA proposed guidelines open the door to biosimilars
Feb 10 Biotech: A "Stock Picker's Delight," Says Morgan Stanley
Feb 10 Sector Snap: Morgan Stanley on biotech drugmakers
Feb 10 $DNDN $IDIX $VRTX $MDVN $CELG $AMGN $IBB $IBX ++biotechs same pattern for day/week. All seem to be basing from pullback/pause. Let's see... by onpaper
Feb 10 Midday Glance: Biotechnology companies
Feb 10 Vanguard Group's Top Sells: 3 Potential Short Candidates
Feb 10 Early Glance: Biotechnology companies
Feb 10 Gate Sniffage: Apple, Amgen, Lowes, Yahoo and Netflix Bucking the Early Trend
Feb 10 Chart of the Day: Amgen
Feb 09 FDA panel of cancer experts voted against use for $AMGN Xgeva in prostate cancer. http://stks.co/2K65 by abubnic
Feb 09 Hep C/Orphan Diseases Driving Big Biotech Potential. $INHX $DNDN $HGSI $REGN $GILD $VPHM $ALXN $ITMN $CELG $AMGN $VRTX http://stks.co/2Jq5 by abubnic
Feb 08 $DNDN Analyst Says FDA Panel Rejection on $AMGN XGEVA Would Not Positively Affect DNDN's PROVENGE, as they Are Not Mutually Exclusive by Benzinga
Feb 08 Days not over but big loser here, made no $$ on $AMGN $SODA $ACHN $IDIX $LNG $VVUS....just sell anything i say im buying, lol! by collegefb81

Profile

Exchange: NASDAQGS       Sector: Healthcare       Industry: Biotechnology

Amgen Inc. is an international biotechnology company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotech firm. The company employs approximately 17,000 staff members. Its products include Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara, Nplate, and Prolia. Epogen and Neupogen were the two most successful biopharmaceutical products at the time of their respective releases. Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology, and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Amgen is up N/A over the last year vs S&P 500 Total Return up N/A, Celgene Corporation up N/A, and Biogen IDEC up N/A.

  • AMGN Total Returns
  • ^SPXTR Total Returns
  • CELG Total Returns
  • BIIB Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Get Quote for

Pro Strategies Featuring AMGN

Did Amgen make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

AMGN Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
AMGN 67.36 0.52 0.78% 59.04B
NWLI 151.01 -1.29 -0.85% 548.17M
ESRX 50.17 -0.11 -0.22% 24.49B
INFY 55.71 -0.59 -1.05% 31.83B
HSNI 35.34 -0.35 -0.98% 2.08B
ACGL 37.93 0.12 0.32% 5.05B
ASTI 0.83 0.02 2.85% 32.31M
JNPR 22.72 -0.46 -1.98% 12.11B
SILC 17.12 0.12 0.71% 117.96M
PTIX 1.99 0.11 5.85% 22.13M
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close